In contrast to the general population, HCC patients have a much lower level of FDX1 expression, while the low expression of FDX1 suggests a poor prognosis, tumor cells acquire a survival advantage over healthy cells by resisting cuproptosis. This evidence concerns the gene FDX1 and hepatocellular carcinoma.